Tech Company Inital Public Offerings
Theseus Pharmaceuticals IPO
On 10/7/2021, Theseus Pharmaceuticals went public.
Transaction Overview
Company Name
Announced On
10/7/2021
Transaction Type
IPO
Amount
$160,000,000
Proceeds Purpose
We intend to use the net proceeds from this offering to fund the continued development of THE-630; to fund the continued development of our EGFR inhibitor program; to fund the research and development of additional pan-variant kinase inhibitor programs; and for general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
210 Broadway St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Theseus Pharmaceuticals is passionately committed to outsmarting cancer resistance. Cancer is constantly mutating, allowing it to evade initially effective oncology treatments. Theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
David Kerstein
Chief Scientific Officer
Victor Rivera
Chief Technical Officer
David Dalgarno
Co-Founder
William Shakespeare
Vice President
Wei-Sheng Huang
Browse more venture capital transactions:
Prev: 10/7/2021: Modern Treasury venture capital transaction
Next: 10/7/2021: Olea Edge Analytics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs